Cizzle Bio's Major Milestone: CIZ1B Biomarker Test Selected for US Cancer Study

Significant Advancement in Lung Cancer Detection

Cizzle Biotechnology Holdings PLC has announced a pivotal development: their CIZ1B biomarker test has been chosen for a significant clinical study at a leading US cancer center. This selection follows early collaboration with Cizzle Bio, Inc., highlighting the test's potential to enhance early lung cancer detection.

Key Details:

• Study Involvement:

  The CIZ1B test will help confirm lung nodules identified by CT scans.

• Strategic Partnership:

  Cizzle Bio, Inc. has secured an exclusive license to develop and market the test in North America.

• Financial Implications:

  Cizzle Biotechnology Holdings PLC will receive milestone payments and royalties from Cizzle Bio, Inc.

Future Outlook:

• First Clinical Lab Registration:

  Expected by September with a full product launch planned for April 2025.

• Revenue Streams:

  Guaranteed minimum advance royalties of USD 2.3 million over 30 months, alongside a 10% royalty on gross revenue.

For more detailed information, read the full article on Morningstar: Cizzle's CIZ1B Biomarker Test Picked for Major US Cancer Study.